S. Thorgeirsson and J. Grisham, Molecular pathogenesis of human hepatocellular carcinoma, Nature Genetics, vol.31, issue.4, pp.339-385, 2002.
DOI : 10.1038/ng0802-339

K. Schulze, S. Imbeaud, E. Letouze, L. Alexandrov, J. Calderaro et al., Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nature Genetics, vol.30, issue.5, pp.505-516, 2015.
DOI : 10.1371/journal.pone.0038686

URL : https://hal.archives-ouvertes.fr/inserm-01159736

Y. Totoki, K. Tatsuno, K. Covington, H. Ueda, C. Creighton et al., Trans-ancestry mutational landscape of hepatocellular carcinoma genomes, Nature Genetics, vol.35, issue.12, pp.1267-73, 2014.
DOI : 10.1186/1471-2105-11-189

J. Marquardt, J. Andersen, and S. Thorgeirsson, Functional and genetic deconstruction of the cellular origin in liver cancer, Nature Reviews Cancer, vol.15, issue.11, pp.653-67, 2015.
DOI : 10.1053/j.gastro.2013.10.013

H. Van-malenstein, J. Van-pelt, and C. Verslype, Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma Molecular classification of hepatocellular carcinoma anno 2011, Cancer Res Eur J Cancer, vol.6947, issue.712, pp.7385-921789, 2009.

W. Huang-da, B. Sherman, and R. Lempicki, Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources, Nature Protocols, vol.99, issue.1, pp.44-57, 2009.
DOI : 10.1038/nprot.2008.211

C. Coulouarn, V. Factor, J. Andersen, M. Durkin, and S. Thorgeirsson, Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties, Oncogene, vol.372, issue.40, pp.3526-3562, 2009.
DOI : 10.1038/onc.2009.211

J. Lamb, E. Crawford, D. Peck, J. Modell, I. Blat et al., The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease, Science, vol.313, issue.5795, pp.1929-1964, 2006.
DOI : 10.1126/science.1132939

D. Hanahan and R. Weinberg, Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-74, 2011.
DOI : 10.1016/j.cell.2011.02.013

R. Cairns, I. Harris, and T. Mak, Regulation of cancer cell metabolism, Nature Reviews Cancer, vol.118, issue.2, pp.85-95, 2011.
DOI : 10.1038/nrc2981

C. Coulouarn, V. Factor, and S. Thorgeirsson, Transforming growth factor-?? gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer, Hepatology, vol.24, issue.2, pp.2059-67, 2008.
DOI : 10.1002/hep.22283

J. Luo, N. Solimini, and S. Elledge, Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction, Cell, vol.136, issue.5, pp.823-860, 2009.
DOI : 10.1016/j.cell.2009.02.024

J. Lee, J. Heo, L. Libbrecht, I. Chu, P. Kaposi-novak et al., A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells, Nature Medicine, vol.149, issue.4, pp.410-416, 2006.
DOI : 10.1111/j.1349-7006.2003.tb01366.x

T. Yamashita, J. J. Budhu, A. Forgues, M. , Y. W. Wang et al., EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features, Gastroenterology, vol.136, issue.3, pp.1012-1036, 2009.
DOI : 10.1053/j.gastro.2008.12.004

J. Zucman-rossi, A. Villanueva, J. Nault, and J. Llovet, Genetic Landscape and Biomarkers of Hepatocellular Carcinoma, Gastroenterology, vol.149, issue.5, pp.1226-1265, 2015.
DOI : 10.1053/j.gastro.2015.05.061

P. Richardson, B. Barlogie, J. Berenson, S. Singhal, S. Jagannath et al., A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma, New England Journal of Medicine, vol.348, issue.26, pp.2609-2626, 2003.
DOI : 10.1056/NEJMoa030288

K. Chen, H. Yu, T. Liu, S. Lee, P. Chen et al., Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation, Journal of Hepatology, vol.52, issue.1, pp.88-95, 2010.
DOI : 10.1016/j.jhep.2009.10.011

S. Minucci and P. Pelicci, Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer, Nature Reviews Cancer, vol.105, issue.1, pp.38-51, 2006.
DOI : 10.1038/nrc1779

Y. Shukla and R. Singh, Resveratrol and cellular mechanisms of cancer prevention, Annals of the New York Academy of Sciences, vol.73, issue.1
DOI : 10.1111/j.1749-6632.2010.05870.x

W. Xu, R. Parmigiani, and P. Marks, Histone deacetylase inhibitors: molecular mechanisms of action, Oncogene, vol.3, issue.37, pp.5541-52, 2007.
DOI : 10.1016/j.bbrc.2005.12.144

H. Schneider, K. Fekir, C. Coulouarn, D. Glaise, C. Aninat et al., Histone deacetylase inhibitors impair NK cell viability and effector functions through inhibition of activation and receptor expression Inflammatory cytokines promote the retrodifferentiation of tumor-derived hepatocyte-like cells to progenitor cells, J Leukoc Biol Hepatology, vol.9160, issue.296, pp.321-312077, 2012.

W. Yeo, H. Chung, S. Chan, L. Wang, R. Lim et al., Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group, Journal of Clinical Oncology, vol.30, issue.27, pp.3361-3368, 2012.
DOI : 10.1200/JCO.2011.41.2395

J. Llovet and V. Hernandez-gea, Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design, Clinical Cancer Research, vol.20, issue.8, pp.2072-2081, 2014.
DOI : 10.1158/1078-0432.CCR-13-0547

R. Lencioni, J. Llovet, G. Han, W. Tak, J. Yang et al., Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial, Journal of Hepatology, vol.64, issue.5
DOI : 10.1016/j.jhep.2016.01.012